Urogen pharma ltd. (URGN)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
REVENUES

-

-

-

18

-

0

283

364

481

327

7,812

0

19

COST OF REVENUES

-

-

-

-

-

0

1,055

318

430

287

295

0

18

GROSS (LOSS) PROFIT

-

-

-

18

-

0

-772

46

51

40

7,517

0

1

OPERATING EXPENSES:
RESEARCH AND DEVELOPMENT EXPENSES

16,588

20,094

9,481

9,996

9,726

11,465

9,574

8,273

7,622

6,761

5,621

3,651

2,664

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

21,973

-

-

-

12,707

-

-

-

-

-

-

-

-

GENERAL AND ADMINISTRATIVE EXPENSES

-

-

13,972

13,775

-

12,552

10,743

10,207

6,069

3,437

2,199

2,300

875

OPERATING LOSS

-38,561

-39,839

-23,453

-23,753

-22,433

-24,017

-21,089

-18,434

-13,640

-10,158

-303

-5,951

-3,538

INTEREST AND OTHER INCOME, NET

768

866

1,201

1,276

989

-

556

408

-

91

5

-248

121

FINANCE INCOME, NET

-

-

-

-

-

-

-

-

258

-

-

-

-

NET LOSS

-37,793

-38,973

-22,252

-22,477

-21,444

-23,716

-20,533

-18,026

-13,382

-10,086

-298

-6,199

-3,417

STATEMENTS OF COMPREHENSIVE LOSS
NET LOSS

-37,793

-38,973

-22,252

-22,477

-21,444

-

-20,533

-18,026

-

-

-

-

-

OTHER COMPREHENSIVE INCOME:
UNREALIZED GAIN ON MARKETABLE SECURITIES

35

-

22

281

-

-

-

-

-

-

-

-

-

COMPREHENSIVE LOSS

-37,758

-39,000

-22,230

-22,196

-21,444

-

-20,533

-18,026

-

-

-

-

-

NET LOSS PER ORDINARY SHARE BASIC AND DILUTED

1.79

-4.09

-1.06

-1.08

1.11

-3.26

-1.28

-1.14

0.88

-0.31

-0.02

-0.07

-1.74

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE

21,158

21,024

20,916

20,833

19,340

15,871

16,092

15,784

15,267

14,304

13,051

9,204

2,307